抗生素、益生菌和皮质类固醇如何改变微生物群及其对癌症免疫检查点抑制剂的影响：综述。
How Could Antibiotics, Probiotics, and Corticoids Modify Microbiota and Its Influence in Cancer Immune Checkpoint Inhibitors: A Review.
机构信息
Medical Oncology Department, University Hospital Lozano Blesa, Zaragoza, Spain.
Aragon Health Research Institute (IIS Aragón), Zaragoza, Spain.
出版信息
Infect Immun. 2021 Aug 16;89(9):e0066520. doi: 10.1128/IAI.00665-20.
Abstract
Immunotherapy has become a new paradigm in oncology, improving outcomes for several types of cancer. However, there are some aspects about its management that remain uncertain. One of the key points that needs better understanding is the interaction between immunotherapy and gut microbiome and how modulation of the microbiome might modify the efficacy of immunotherapy. Consequently, the negative impact of systemic antibiotics and corticosteroids on the efficacy of immunotherapy needs to be clarified.
摘要
免疫疗法已成为肿瘤学的新范例，改善了多种癌症的预后。然而，其管理方面仍存在一些不确定因素。需要更好地理解的关键点之一是免疫疗法与肠道微生物组之间的相互作用，以及微生物组的调节如何改变免疫疗法的疗效。因此，需要阐明全身用抗生素和皮质类固醇对免疫疗法疗效的负面影响。
相似文献
1
How Could Antibiotics, Probiotics, and Corticoids Modify Microbiota and Its Influence in Cancer Immune Checkpoint Inhibitors: A Review.抗生素、益生菌和皮质类固醇如何改变微生物群及其对癌症免疫检查点抑制剂的影响：综述。
Infect Immun. 2021 Aug 16;89(9):e0066520. doi: 10.1128/IAI.00665-20.
2
Gut Microbiota in Cancer Immune Response and Immunotherapy.肠道微生物群在癌症免疫反应和免疫治疗中的作用。
Trends Cancer. 2021 Jul;7(7):647-660. doi: 10.1016/j.trecan.2021.01.010. Epub 2021 Mar 2.
3
Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.肠道微生物组和微生物衍生代谢物在癌症免疫检查点阻断免疫治疗中的作用。
Genome Med. 2021 Jun 23;13(1):107. doi: 10.1186/s13073-021-00923-w.
4
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy.免疫检查点抑制剂与癌症治疗中抗生素相互作用的分析。
Front Med. 2022 Jun;16(3):307-321. doi: 10.1007/s11684-022-0927-0. Epub 2022 Jun 1.
5
Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality.通过调控肠道和肿瘤微生物群来进行免疫检查点抑制剂治疗：从梦想走向现实。
Trends Mol Med. 2023 Nov;29(11):897-911. doi: 10.1016/j.molmed.2023.08.004. Epub 2023 Sep 11.
6
The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy.肺部微生物组对肺癌发生、免疫和免疫治疗的影响。
Trends Cancer. 2020 Feb;6(2):86-97. doi: 10.1016/j.trecan.2019.12.007. Epub 2020 Jan 18.
7
Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.调控肠道菌群以增强免疫检查点抑制剂的治疗效果。
Front Immunol. 2021 Jun 29;12:669150. doi: 10.3389/fimmu.2021.669150. eCollection 2021.
8
Gut microbiome in modulating immune checkpoint inhibitors.肠道微生物组在调节免疫检查点抑制剂中的作用。
EBioMedicine. 2022 Aug;82:104163. doi: 10.1016/j.ebiom.2022.104163. Epub 2022 Jul 15.
9
Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.肠道微生物组在癌症免疫治疗中的调节作用：免疫检查点抑制剂阻断的新范例。
Cancer Med. 2021 Feb;10(3):1141-1154. doi: 10.1002/cam4.3694. Epub 2020 Dec 25.
10
A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.癌症中新的生物学三角：肠道微生物群、免疫检查点抑制剂和抗生素。
Clin Transl Oncol. 2021 Dec;23(12):2415-2430. doi: 10.1007/s12094-021-02659-w. Epub 2021 Jun 14.
引用本文的文献
1
Long COVID and gut candidiasis: What is the existing relationship?长新冠与肠道假丝酵母菌病：现有关系如何？
World J Gastroenterol. 2024 Oct 7;30(37):4104-4114. doi: 10.3748/wjg.v30.i37.4104.
2
Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer.抗生素、皮质类固醇和微生物群对非小细胞肺癌患者免疫治疗疗效的影响。
Heliyon. 2024 Jul 1;10(13):e33684. doi: 10.1016/j.heliyon.2024.e33684. eCollection 2024 Jul 15.
3
The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.肠道微生物组：从生物标志物到肺癌患者免疫治疗反应的新型治疗策略。
Curr Oncol. 2023 Oct 24;30(11):9406-9427. doi: 10.3390/curroncol30110681.
4
Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis.乙酰氨基酚暴露对接受免疫检查点抑制剂治疗晚期非小细胞肺癌患者结局的影响：倾向评分匹配分析。
Curr Oncol. 2023 Sep 1;30(9):8117-8133. doi: 10.3390/curroncol30090589.
5
Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study.既往糖皮质激素暴露对晚期非小细胞肺癌患者接受免疫检查点抑制剂治疗结局的影响：一项回顾性观察性研究。
Cancer Chemother Pharmacol. 2022 Apr;89(4):529-537. doi: 10.1007/s00280-022-04416-4. Epub 2022 Mar 18.
6
A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.免疫检查点抑制剂在晚期肺癌中的安全性特征网络比较。
Front Immunol. 2021 Dec 3;12:760737. doi: 10.3389/fimmu.2021.760737. eCollection 2021.
7
Special Collection on the Microbiome and Infection.微生物组与感染专题文集
Infect Immun. 2021 Aug 16;89(9):e0035621. doi: 10.1128/IAI.00356-21.
8
Biodiversity of Gut Microbiota: Impact of Various Host and Environmental Factors.肠道微生物组的多样性：各种宿主和环境因素的影响。
Biomed Res Int. 2021 May 12;2021:5575245. doi: 10.1155/2021/5575245. eCollection 2021.
本文引用的文献
1
Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma.在美国晚期非小细胞肺癌、黑色素瘤或尿路上皮癌的真实世界肿瘤学实践中，接受免疫检查点抑制剂治疗的患者基线全身使用皮质类固醇与总生存期及下次治疗时间的关联。
Oncoimmunology. 2020 Oct 5;9(1):1824645. doi: 10.1080/2162402X.2020.1824645.
2
NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis.非小细胞肺癌免疫治疗疗效与抗生素使用：系统评价与荟萃分析。
J Thorac Oncol. 2020 Jul;15(7):1147-1159. doi: 10.1016/j.jtho.2020.03.002. Epub 2020 Mar 12.
3
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.抗生素和质子泵抑制剂治疗的非小细胞肺癌患者的化疗和阿特珠单抗疗效：OAK 和 POPLAR 试验的汇总事后分析。
Ann Oncol. 2020 Apr;31(4):525-531. doi: 10.1016/j.annonc.2020.01.006. Epub 2020 Jan 16.
4
Immune related adverse events and response to immunotherapy: Focus on corticosteroids.免疫相关不良事件及免疫治疗反应：聚焦于皮质类固醇
Lung Cancer. 2020 Jul;145:225. doi: 10.1016/j.lungcan.2020.02.009. Epub 2020 Feb 17.
5
Probiotic and strains possess safety characteristics, antiviral activities and host adherence factors revealed by genome mining.益生菌及其菌株具有通过基因组挖掘揭示的安全特性、抗病毒活性和宿主黏附因子。
EPMA J. 2019 Sep 5;10(4):337-350. doi: 10.1007/s13167-019-00184-z. eCollection 2019 Dec.
6
Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients.抗生素使用与癌症患者免疫检查点抑制剂的疗效：对2740例癌症患者的汇总分析
Oncoimmunology. 2019 Sep 23;8(12):e1665973. doi: 10.1080/2162402X.2019.1665973. eCollection 2019.
7
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.单独或联合使用糖皮质激素诱导的肿瘤坏死因子受体相关蛋白激动剂与纳武利尤单抗治疗晚期实体瘤患者的安全性、耐受性和潜在临床活性：一项 I/IIa 期剂量递增和队列扩展临床试验。
JAMA Oncol. 2020 Jan 1;6(1):100-107. doi: 10.1001/jamaoncol.2019.3848.
8
The Human Microbiome and Checkpoint Inhibition: Potential Benefits From Antibiotic Stewardship.人类微生物组与检查点抑制：抗生素管理的潜在益处
Clin Infect Dis. 2020 Jul 27;71(3):701-702. doi: 10.1093/cid/ciz1003.
9
Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?肠道微生物群：改善抗肿瘤治疗的新靶点？
Int J Mol Sci. 2019 Sep 17;20(18):4584. doi: 10.3390/ijms20184584.
10
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.接受纳武单抗治疗的晚期黑色素瘤、肾细胞癌或非小细胞肺癌患者的五年生存率及相关因素
JAMA Oncol. 2019 Oct 1;5(10):1411-1420. doi: 10.1001/jamaoncol.2019.2187.
Zotero 插件